The integration of Ro5's AI Chemistry Platform will facilitate more efficient drug discovery and development processes for Juvenescence.

Charles Dazler Knuff, CEO of Ro5, expressed enthusiasm for the acquisition, highlighting the potential of their combined efforts to transform patient care through AI innovation.

Juvenescence is focused on developing treatments for aging-related diseases, with a pipeline that includes programs in cognition, cardio-metabolism, immunity, and cellular repair.

Ro5's platform utilizes a Biomedical Knowledge Graph with over 85 million nodes and 400 million relationships to identify novel drug targets and associations in biological processes.

The platform employs advanced neural network architectures to analyze molecular properties and pharmacological behavior, aiming to reduce drug development time and costs.

Juvenescence Limited has acquired Ro5 Inc., an AI drug discovery company, to enhance its research and development capabilities in therapeutics aimed at extending healthy lifespan.

The acquisition supports Juvenescence's strategic partnership with Abu Dhabi-based M42, which aims to create a robust pipeline of AI-enabled medicines.

The collaboration combines M42's strengths in clinical data and healthcare with Juvenescence's drug discovery platforms, with Ro5's technology playing a crucial role.

The company's founding team has a successful history in biopharma, including significant deals totaling $30 billion in peak sales, and aims to leverage cutting-edge AI tools for drug development.

Richard Marshall, CEO of Juvenescence, stated that Ro5's experienced team and toolkit complement Juvenescence's goals and align with M42's ambitions in AI and machine learning for health improvements.

This acquisition follows Juvenescence's successful first close of a $76 million Series B-1 financing round led by M42, with additional investments anticipated later in 2025.

Marshall highlighted the importance of combining AI and machine learning with traditional drug development methods to achieve clinical effectiveness.